Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

Chief Strategy and Business Officer Atul Dandekar exercised and sold 7,500 shares of common stock in a transaction valued at approximately $190,000 on April 29, 2026. The article is a routine insider transaction disclosure with no accompanying operational or financial update. Market impact is likely minimal unless part of a broader pattern of insider selling.

Analysis

Chief Strategy and Business Officer Atul Dandekar exercised and sold 7,500 shares of common stock in a transaction valued at approximately $190,000 on April 29, 2026. The article is a routine insider transaction disclosure with no accompanying operational or financial update. Market impact is likely minimal unless part of a broader pattern of insider selling.